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PURPOSE: The dura mater bioprosthesis was developed in the Department of Cardiopneumology of the Hospital das
Clínicas of the University of São Paulo Medical School in 1971. Here, we present the clinical results of the dura mater
bioprosthesis over 30 years of follow-up.
METHODS: We studied 70 consecutive patients who underwent mitral or tricuspid valve replacement with a dura
mater bioprosthesis between January 1971 and August 1972.
RESULTS: The early mortality was 10% (7 patients). The follow-up was 87% complete (9 patients were lost to follow-
up). Two patients were alive and asymptomatic 30 years after valve replacement; 33 patients underwent reoperations due to
valve dysfunction, and 19 died during the follow-up period. At 30 years, the actuarial survival was 49.2 ± 8.6%; freedom
from rupture, 27.0 ± 10.2%; freedom from calcification, 78.8 ± 8.6%; and freedom from reoperation, 18.8 ± 7.5%.
CONCLUSIONS: The dura mater bioprosthesis played an important role in the treatment of patients with mitral and
tricuspid valve disease. The low rate of thromboembolism and the long period of follow-up without evidence of valve
dysfunction, which occurred for several of our patients, are important characteristics of these bioprosthesis.
DESCRIPTORS: Dura mater. Bioprosthesis. Glycerol. Valve disease. Valve surgery.
The dura mater bioprosthesis was
an original contribution developed in
1971 in the Department of Cardio-
pneumology of the Hospital das
Clínicas, University of São Paulo
Medical School1,2. In the 1960s, the
Starr-Edwards ball-valve prosthesis
was the only valve substitute avail-
able. This prosthesis was associated
with a high incidence of thromboem-
bolic events, mainly involving mitral
valve replacement, with a prevalence
of cerebrovascular accidents over 4
years of evolution of 27.4%3. The ho-
mologous dura mater bioprosthesis
was developed for the purpose of pre-
venting this serious complication. The
initial and midterm results with this
bioprosthesis were satisfactory. After 6
years of follow-up, some patients pre-
sented with fatigue injuries, mani-
fested as tears in the dura mater cusps.
Despite this complication, the low rate
of thromboembolism indicated the use
of this prosthesis instead of the Starr-
Edwards prosthesis.
In the early 1980s, the use of the
dura mater bioprosthesis was discon-
tinued. The heterologous porcine and
pericardial bioprosthesis, prepared
with glutaraldehyde, became the first
choice for use in heart valve replace-
ment due to the higher availability, su-
perior quality control, and lower rates
of associated structural valve deterio-
ration observed during short-term fol-
low-up.
In this paper, we present the clini-
cal evolution of the first series of 70
patients with dura mater bioprosthesis
in the mitral and tricuspid positions,
30 years after the operation.
PATIENTS  AND  METHODS
Seventy consecutive patients un-
derwent mitral (68 patients) or tricus-
pid (2 patients) valve replacement
with a dura mater bioprosthesis from
January 1971 to August 1972 (Fig. 1).
The clinical follow-up was concluded
in August 2002.
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Table 2 - Reoperation: causes, time of event, and follow-up period of events.
Cause No. of cases Time of event Follow- up period of event
(years) 0-10 y 11–20 y 21-30 y
Rupture 23 (70%) 3 – 28 9 (40%) 7 (30%) 7 (30%)
(mean= 15)
Calcification 5 (15%) 8 – 17 1 (20%) 4 (80%)
(mean= 12.4)
Technical failure 3 (9%) 1 – 3 3 (100%)
(mean= 2)
Paravalvar leak 1 (3%) Immediate 1 (100%)
Hemolysis 1 (3%) 8 1 (100%)
TOTAL 33 (100%)
Table 1 - Causes of Late Mortality.
Cause of mortality Patients %
Heart failure 7 36.8
Cerebrovascular accident 2 10.5
Arrhythmia 2 10.5
Bronchopneumonia 2 10.5
Endocarditis 2 10.5
Acute abdominal disease 1 5.3
Mesenteric thrombosis 1 5.3
Unknown 2 10.5
TOTAL 19 100
Figure 2 - Actuarial survival.
Figure 1- Model of implanted dura mater
bioprosthesis.
Forty-two patients (60%) were fe-
male and 28 (40%) were male. The age
of the patients ranged from 17 to 54
years. The valve lesions identified
preoperatively were as follows: mitral
insufficiency in 26 patients (37.1%),
double mitral lesions in 20 (28.6%),
mitral stenosis in 3 (4.3%), tricuspid
insufficiency in 1 (1.4%), thromboem-
bolism due to a Starr-Edwards mitral
prostheses in 18 (25.7%), infective en-
docarditis in 1 (1.4%), and Ebstein’s
disease in 1 (1.4%).
Clinical information was obtained
from the patients through clinical ex-
amination, letter, or telephone contact,
or from clinical cardiologists’ reports.
The follow-up was completed on 87%
of patients (9 patients were lost to fol-
low-up) completed over a closing pe-
riod of 6 months, with a cumulative
follow-up period of 555 years and an
average follow-up interval of 10.3
years.
Definitions of complications, as
well as data analysis and reporting of
results, are in accordance with recom-
mended guidelines4.
RESULTS
Hospital mortality was 10% (7 pa-
tients), which was attributable to heart
failure in 5 patients (71.4%), a stroke
in 1 patient (14.3%), and bronchop-
neumonia in 1 patient (14.3%). Five of
the 7 patients presented preoperatively
with neurologic deficits caused by
Starr-Edwards valve thrombosis and
underwent emergency operations in a
state of hemodynamic instability.
Nineteen died during the late fol-
low-up period from a variety of causes
(Table 1). Late mortality was considered
as valve-related in 5 patients; 2 patients
had prosthetic valve endocarditis, 2 pa-
tients had a stroke, and 1 patient had
mesenteric thrombosis. Thirty-three pa-
tients underwent reoperations during
the follow-up period due to valve dys-
function (Table 2).
During the late follow-up period, 9
patients were lost to follow-up, and 2
were alive 30 years after the surgery.
In our patient population, the actuarial
survival was 49.2% ±8.6% (Fig. 2);
freedom from rupture, 27.0% ±10.2%
(Fig. 3); freedom from calcification,
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Figure 3 - Actuarial freedom from rupture.
Figure 5 - Actuarial freedom from structural valve dysfunction.
Figure 4 - Actuarial freedom from calcification.
78.8% ±8.6% (Fig. 4); freedom from
structural valve deterioration, 20.9%
±8.3% (Fig. 5); freedom from
reoperation, 18.8% ±7.5% (Fig. 6); and
freedom from thromboembolism,
91.4% ±4.3% (Fig. 7).
DISCUSSION
The thromboembolic events asso-
ciated with Starr-Edwards prostheses
represent one of the most serious com-
plications related to mechanical pros-
theses. In mitral valve replacement, the
rate of thromboembolism is high, and
several patients have experienced per-
manent neurologic sequelae. The new
mechanical prostheses offer low rates
of thromboembolism, although pa-
tients are kept under anticoagulant
therapy and are subjected to its risks.
New materials and structural modifica-
tions of mechanical and biological
prostheses have been evaluated in sev-
eral clinical and experimental studies
to identify means of reducing the risk
of thromboembolic events.
Following experimental studies on
homologous dura mater preserved in
glycerol by Pigossi et al.5, this biologi-
cal tissue was used as an implant by
several surgical groups in the early
1970s. After experimental study, we
observed that homologous dura mater
was an appropriate tissue for making
bioprosthetic cusps for heart valve re-
placement during cardiac surgery. The
structure of dura mater, consisting of
2 layers of collagen fibers disposed in
many directions, confers great resist-
ance and pliability, which are both es-
sential to valve function.
The initial clinical results with
dura mater bioprostheses were very
favorable, and this prosthesis soon be-
came our first choice for use in heart
valve replacement. The presentation of
our results stimulated a great number
of surgeons and institutions to use or
study this bioprosthesis6-12. Harasaki et
al.13, comparing aortic bovine valves
treated with glutaraldehyde and hu-
man dura mater bioprostheses treated
with glycerol, showed that dura mater
bioprostheses were more durable.
The main objection to the use of
dura mater bioprostheses relates to the
use of glycerol for their preparation.
That is, there is concern that glycerol
is not an efficient sterilizing agent, al-
though none of our patients experi-
enced early infective endocarditis. The
cases of infective endocarditis ob-
served in our series all occurred dur-
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Figure 6 - Actuarial freedom from reoperation.
Figure 7 - Actuarial freedom from thromboembolism.
Figure 8 - Dura mater bioprosthesis recovered
25 years after implantation. Note the
preservation of the tissue in a great portion of
the valve.
ing the late postoperative period (5
years) and therefore were not related to
the sterilization method.
The dura mater bioprosthesis is as-
sociated with low thrombogenicity, but
structural deterioration constitutes the
main reason for reoperation14,15. The
main complication was tissue tears, and
these were observed after 6 years of
follow-up. A higher incidence of this
complication occurred after 10 to 25
years of follow-up in patients who un-
derwent mitral valve replacement.
Rupture did not occur in patients who
underwent tricuspid valve replace-
ment, perhaps because of the lower
hemodynamic stress associated with
right ventricular systole16. The occur-
rence of rupture between 10 and 25
years postoperatively is an observation
favorable to the dura mater
bioprosthesis and indicative of its du-
rability. The actuarial freedom from
rupture at 30 years was 27.0% ±10.2%.
Dura mater bioprostheses are asso-
ciated with low rates of calcification.
This is probably because they are com-
posed of a homologous tissue, and are
dehydrated with 98% glycerol without
chemical interaction with the amino
radicals that compose the collagen fi-
bril protein structures. At 30 years, the
actuarial freedom from calcification
was 78.8% ±8.6%.
With the Carpentier-Edwards stand-
ard porcine bioprosthesis, Jamieson et
al. demonstrated that freedom from
structural valve deterioration after mi-
tral valve replacement was 21.% ±3.9%
at 15 years17 and 8.5% ±3.4% at 18
years18. In contrast, freedom from struc-
tural dysfunction was 20.9% ±8.3% at
30 years in our study, although we
must consider the limited number of
patients compared with the other se-
ries. Whereas our data do not demon-
strate overall superiority of the dura
mater prosthesis, they do suggest that
calcification rates are lower and that
rupture occurs later with this
bioprosthesis than with others.
Biological prostheses often fail af-
ter implantation, and patients usually
must undergo reoperation, primarily
because of structural valve deteriora-
tion. The freedom from reoperation in
our series of 70 patients was 18.8%
±7.5% at 30 years. Dura mater
bioprostheses were associated with a
lower incidence of calcification com-
pared with pericardial and porcine
prostheses treated with glutaraldehyde
(Fig. 8). Rupture occurred more fre-
quently than calcification. However,
we must consider that this series only
included adult patients, and calcifica-
tion occurs more frequently in infants.
The learning curve explains the
cases of technical failure observed in
our study. At that time, surgeons were
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prepared to implant Starr-Edwards
prostheses, which do not require atten-
tion to the position of the fixation
stitches. In the case of bioprostheses,
misplaced stitches can interfere with
the frame, holding the cusps and caus-
ing valvular insufficiency.
Using electron microscopy, Allen
et al.19 studied 12 dura mater
bioprostheses removed in reoperations
after 23 to 108 months of implanta-
tion. These authors observed evidence
of cellular remodeling and concluded
that the long durability of these
bioprostheses may relate to factors
such as the preservation of collagen
fibers by glycerol and the viability of
fibroblasts and macrophages inside the
dura mater tissue. These findings indi-
cate that dura mater bioprostheses are
structures actively involved in the
process of surface degeneration and
remodeling.
At our institution, a protocol study
for the selective fixation of dura mater
with glutaraldehyde is being devel-
oped in order to improve resistance to
rupture without compromising cusp
pliability. Three patients received
these new dura mater bioprostheses 5
years ago and they have experienced
a normal evolution up until now.
In conclusion, the dura mater
bioprosthesis may offer some advan-
tages over other prostheses including
low thrombogenicity, superior durabil-
ity, and good pliability. However, the
dura mater bioprosthesis has 2 opera-
tional problems that limit its use—the
reliability of the sterilization process
and the low availability. Only by solv-
ing these problems will we be able to
resume the use of dura mater
bioprostheses.
RESUMO
PUIG LB e col. - Bioprótese de dura
mater mitral e tricúspide: 30 anos
de acompanhamento. Rev. Hosp.
Clín. Fac. Med. S. Paulo 58(3):
163-168, 2003.
A bioprótese de dura-mater foi de-
senvolvida no Hospital das Clínicas da
Faculdade de Medicina da Universida-
de de São Paulo em 1971. Este traba-
lho apresenta os resultados clínicos
com 30 anos de seguimento.
MÉTODOS: Foram estudados 70
pacientes consecutivos com biopró-
tese mitral ou tricúspide, operados de
janeiro de 1971 a agosto de 1972.
RESULTADOS: A mortalidade
imediata foi 10% (7 pacientes). Dois
pacientes evoluem bem com a biopró-
tese de dura-máter, 9 não tem seguimen-
to atualizado, 33 apresentaram disfun-
ção da bioprotese e foram reoperados e
19 faleceram durante a evolução tardia.
A curva atuarial de sobrevida foi de
49,2 ± 8,6%, livre de rotura, 27,0 ±
10,2%, livre de calcificação, 78,8 ± 8,6%
e livre de reoperação, 18,8% ± 7,5%.
CONCLUSÕES: A bioprótese de
dura-mater teve mais importante papel
no tratamento de pacientes com lesão
das valvas mitral e tricúspide. A baixa
taxa de tromboembolismo e o longo
período de seguimento sem disfunção
valvar em vários pacientes são impor-
tantes características desta bioprótese.
DESCRITORES: Dura-mater. Bio-
prótese valvar mitral e tricúspide.
Glicerina. Cirurgia valvar.
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